KOD
Kodiak Sciences Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 78 | +7 | 23.28M | $907.00M | +13 | −5 |
| Q1 2026 | 73 | +1 | 22.77M | $867.18M | +7 | −7 |
| Q4 2025 | 73 | 0 | 22.52M | $629.54M | +1 | n/a |
| Q3 2025 | 18 | +2 | 13.89M | $227.40M | +2 | n/a |
| Q2 2025 | 13 | 0 | 11.40M | $42.51M | +1 | −1 |
| Q1 2025 | 10 | +1 | 5.74M | $16.11M | +1 | n/a |
| Q4 2024 | 9 | -1 | 5.98M | $59.47M | +2 | −3 |
| Q3 2024 | 9 | +3 | 2.45M | $6.41M | +3 | n/a |
| Q2 2024 | 6 | n/a | 2.71M | $6.38M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | D. E. Shaw & Co. ✦ | 945.15K | n/a | $2.22M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 2 | Geode Capital Management ✦ (passive) | 755.96K | n/a | $1.78M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | Renaissance Technologies ✦ | 708.80K | n/a | $1.67M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Marshall Wace ✦ | 166.43K | n/a | $391,099 | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Two Sigma Investments ✦ | 124.41K | n/a | $292,366 | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Millennium Management ✦ | 12.76K | n/a | $29,979 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 186 holders, 57.91M shares, $2.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
Director, 10% owner · 1.42K sh @ 85.89 · $121,614
Director, 10% owner · 84 sh @ 85.89 · $7,214
Director, 10% owner · 10.38K sh @ 84.24 · $874,517
Director, 10% owner · 1.20K sh @ 85.40 · $102,057
Director, 10% owner · 20.03K sh @ 85.40 · $1.71M
Director, 10% owner · 619 sh @ 84.24 · $52,146
Director, 10% owner · 44.69K sh @ 61.63 · $2.75M
Director, 10% owner · 2.67K sh @ 61.63 · $164,293
Director, 10% owner · 61 sh @ 80.52 · $4,912
Director, 10% owner · 8.02K sh @ 64.43 · $516,774
Open-market sales (S)
No open-market insider sales in our coverage window.
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
35.0% of class · View original SEC filing ↗